Baird Financial Group Inc. Reduces Position in Humana Inc. $HUM

Key Points

• Baird Financial Group Inc. has decreased its stake in Humana Inc. by 11.9%, now holding shares valued at $2.91 million.
• Humana recently reported $6.27 earnings per share, which fell short of analysts' expectations, alongside a revenue of $32.39 billion for the last quarter.
• The company announced a quarterly dividend of $0.885 per share, reflecting an annualized dividend of $3.54 and a yield of 1.1%.

Baird Financial Group Inc. lowered its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 11.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,007 shares of the insurance provider's stock after selling 1,487 shares during the quarter. Baird Financial Group Inc.'s holdings in Humana were worth $2,913,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co purchased a new position in shares of Humana during the first quarter worth about $34,000. Garde Capital Inc. purchased a new position in Humana during the first quarter worth about $36,000. Zions Bancorporation National Association UT purchased a new position in Humana during the first quarter worth about $37,000. Finally, Whipplewood Advisors LLC raised its holdings in Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Price Performance

HUM stock traded up $0.33 during trading on Wednesday, reaching $273.35. 4,315,593 shares of the company were exchanged, compared to its average volume of 1,734,826. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock's 50 day moving average price is $263.18 and its 200 day moving average price is $256.79. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $333.79. The company has a market cap of $32.88 billion, a P/E ratio of 20.98, a PEG ratio of 1.82 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter last year, the business posted $6.96 earnings per share. The business's revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio (DPR) is 27.17%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on HUM shares. Morgan Stanley cut their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Barclays increased their price target on shares of Humana from $275.00 to $315.00 and gave the stock an "equal weight" rating in a report on Friday, September 5th. Truist Financial cut their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Piper Sandler cut their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a report on Thursday, July 31st. Finally, Bank of America boosted their price objective on shares of Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $289.24.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.